Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. (Q38042714)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

ChEBI release 2020-05-28

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Rachel Huelin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Talia S Foster

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Joaquin F Mould

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Pharmacoeconomics & Outcomes Research

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

505-523

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22971036%20AND%20SRC:MED&resulttype=core&format=json

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

13 February 2020

cites work

1 reference

The burden of illness of rheumatoid arthritis

21 January 2018

1 reference

Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States

21 January 2018

1 reference

Osteoarthritis: an overview of the disease and its treatment strategies.

21 January 2018

1 reference

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

21 January 2018

1 reference

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

21 January 2018

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.

21 January 2018

1 reference

Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease

21 January 2018

1 reference

Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents

21 January 2018

1 reference

Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis

21 January 2018

1 reference

The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis.

21 January 2018

1 reference

An economic model of long-term use of celecoxib in patients with osteoarthritis

21 January 2018

1 reference

Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration

21 January 2018

1 reference

The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis

21 January 2018

1 reference

Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective

21 January 2018

1 reference

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

21 January 2018

1 reference

A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis

21 January 2018

1 reference

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland

21 January 2018

1 reference

Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands

21 January 2018

1 reference

Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis

21 January 2018

1 reference

Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population

21 January 2018

1 reference

Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis

21 January 2018

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec

21 January 2018

1 reference